Researchers from the University of Barcelona and University of Oregon have developed a DNA-based therapy that dramatically lowers LDL cholesterol without statins. The treatment uses tiny DNA molecules called polypurine hairpins to block PCSK9, a protein that prevents cells from clearing bad cholesterol from the blood. By silencing the PCSK9 gene, the therapy boosts LDL receptor levels, allowing the body to pull more cholesterol out of circulation. Early results show nearly 50% reductions in LDL cholesterol. This approach could offer a powerful alternative for people who cannot tolerate statins or need additional cholesterol control, potentially reducing the risk of atherosclerosis and heart disease.
